<DOC>
	<DOC>NCT01811576</DOC>
	<brief_summary>The primary objective of this study is to evaluate the clinical effect of TV-1106.</brief_summary>
	<brief_title>Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Patient agrees to provide written informed consent and to comply with the study protocol after reading the informed consent and discussing the study with the investigator. Males and females between 23 and 65 years of age must have a confirmed diagnosis of adult GHD, either adult onset (AO) GHD due to hypothalamicpituitary disease or childhood onset (CO) GHD that is either idiopathic or due to hypothalamicpituitary disease or due to genetic causes. Diagnosis of GH deficiency must be confirmed by documented (medical records) diagnostic testing. Patients should have been treated with a stable dose of daily rhGH for at least 3 months prior to screening. Other criteria apply. Patients with history or clinical evidence of active or chronic diseases that could confound results of the study or put the subject at undue risk as determined by the investigator. Patients with known active malignancy Patients with history of malignancy other than intracranial tumor causing GHD (excluding surgically cured basal cell or squamous cell cancer of the skin with documented 6 month remission) Patients with evidence of pituitary adenoma or other intracranial tumor within 12 months of enrollment, which is on day 0 (baseline, Visit 3) Patients without magnetic resonance imaging (MRI) or computerized tomography (CT) data to document tumor stability within the 12 months prior to enrollment, which is on day 0 (baseline, Visit 3) Presence of PraderWilli syndrome, Turner's syndrome, untreated adrenal insufficiency, active acromegaly in the past 5 years, or active Cushing's syndrome in the past 1 year. Other criteria apply.</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Growth hormone deficiency</keyword>
	<keyword>Insulin-like growth factor I (IGF-I)</keyword>
	<keyword>TV-1106</keyword>
</DOC>